Articles

VerifyNow,

The year 2013 has brought us several important clinical trials that have changed the way interventional cardiologists approach and treat patients with stable coronary artery disease. These trials...

University of Maryland Medical Center Genetic-Testing Program Cardiac Stent

Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their genes. As part...

Prof. Dr. Béla Merkely and Dr. Péter Sótonyi at Semmelweis Egyetem Kardiológiai Központ in Hungary completed the first patient implant of the Barostim neo device for...

Merck FDA Approval Liptruzet

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved Liptruzet (ezetimibe and atorvastatin) tablets for the treatment...

The U.S. Food and Drug Administration approved Kcentra (prothrombin complex concentrate, human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major...

A study led by researchers at the University of North Carolina indicates a newly approved blood thinner blocks a key component of the human blood clotting system and may increase the risk and...

CHAMPION PHOENIX clinical study anti-platelet therapy cangrelor ACC 13

The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the...

Rox Medical announced enrollment of the first U.K. patients in the CONTROL-HTN international randomized controlled trial of the Rox Flow procedure for the treatment of resistant hypertension.

March 25, 2013 — The largest randomized study of the vitamin niacin in patients with occlusive arterial disease (narrowing of the arteries) has shown a significant increase in adverse side effects...

Accumetrics Verify Now ACC 2013 Antiplatelet Therapy Blood Testing Pharmaceutica

Accumetrics Inc. announced the presentation of a series of important data that solidifies the clinical utility of platelet reactivity testing. Real world outcomes data in high-risk patients...